Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 multiple ascending dose (Mad) study of Incb054707 assessing safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the Janus kinase (JAK) 1 selective inhibitor INCB054707 in healthy participants

Next Previous
Trial Profile

A phase 1 multiple ascending dose (Mad) study of Incb054707 assessing safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the Janus kinase (JAK) 1 selective inhibitor INCB054707 in healthy participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Povorcitinib (Primary)
  • Indications Hidradenitis suppurativa; Prurigo nodularis; Vitiligo
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 21 Apr 2022 New trial record
  • 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top